Candel Therapeutics, Inc. (CADL)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 9.59 |
| Open | 9.70 |
| Bid | 10.76 x 400 |
| Ask | 10.89 x 200 |
| Day's range | 9.44 - 10.83 |
| 52-week range | 0.66 - 11.40 |
| Volume | |
| Avg. volume | 5,593,218 |
| Market cap | 317.833M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
- Simply Wall St.
Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
Key Insights The considerable ownership by retail investors in Candel Therapeutics indicates that they collectively...
- Zacks
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
© 2024 Yahoo. All rights reserved.